Muzafar A Macha

List of Publications by Year
in descending order

59 papers	2,299 citations	186265 28 h-index	223800 46 g-index
61 all docs	61 docs citations	61 times ranked	3257 citing authors

#	Article	IF	Citations
1	Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Molecular Cancer, 2022, 21, 79.	19.2	219
2	Mucins in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Implications. Journal of Thoracic Oncology, 2015, 10, 19-27.	1.1	110
3	Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. Biomedicine and Pharmacotherapy, 2022, 150, 113054.	5.6	91
4	Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Advanced Drug Delivery Reviews, 2015, 81, 16-33.	13.7	89
5	Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 266.	8.6	81
6	Prognostic significance of nuclear pSTAT3 in oral cancer. Head and Neck, 2011, 33, 482-489.	2.0	79
7	Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Cancer Letters, 2013, 341, 166-177.	7.2	77
8	Natural products: a hope for glioblastoma patients. Oncotarget, 2018, 9, 22194-22219.	1.8	77
9	MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis, 2012, 33, 1953-1964.	2.8	76
10	Claudin-1, A Double-Edged Sword in Cancer. International Journal of Molecular Sciences, 2020, 21, 569.	4.1	76
11	Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Molecular Cancer, 2021, 20, 2.	19.2	76
12	MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers. Current Pharmaceutical Design, 2014, 20, 5287-5297.	1.9	71
13	The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Cellular Oncology (Dordrecht), 2021, 44, 1209-1229.	4.4	71
14	Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-ÂB and STAT3 pathways in head and neck cancer cells. Carcinogenesis, 2011, 32, 368-380.	2.8	69
15	Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 12.	17.1	68
16	Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Journal of Hematology and Oncology, 2012, 5, 68.	17.0	65
17	Promoter hypermethylation in Indian primary oral squamous cell carcinoma. International Journal of Cancer, 2010, 127, 2367-2373.	5.1	56
18	Identification of proteins secreted by head and neck cancer cell lines using LCâ€MS/MS: Strategy for discovery of candidate serological biomarkers. Proteomics, 2011, 11, 2363-2376.	2.2	56

#	Article	IF	Citations
19	Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 617281.	3.7	53
20	Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Oncotarget, 2015, 6, 40295-40309.	1.8	46
21	Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. Head and Neck, 2009, 31, 1423-1430.	2.0	44
22	Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget, 2017, 8, 20961-20973.	1.8	41
23	Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. International Journal of Cancer, 2009, 124, 2098-2105.	5.1	40
24	14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in Head and Neck cancer cells. BMC Cancer, 2010, 10, 655.	2.6	39
25	Therapeutic Effects of Curcumol in Several Diseases; An Overview. Nutrition and Cancer, 2021, 73, 181-195.	2.0	39
26	Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: Potential role in therapy. Cancer Letters, 2013, 336, 270-280.	7.2	37
27	Emerging therapeutic potential of graviola and its constituents in cancers. Carcinogenesis, 2018, 39, 522-533.	2.8	33
28	Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 4584.	4.1	29
29	MUC4 regulates cellular senescence in head and neck squamous cell carcinomaÂthrough p16/Rb pathway. Oncogene, 2015, 34, 1698-1708.	5.9	28
30	The canonical Wnt pathway regulates the metastasisâ€promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Molecular Oncology, 2016, 10, 224-239.	4.6	28
31	Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-Î²1/FAK/ERK pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2538-2549.	3.8	28
32	Guggulsterone Targets Smokeless Tobacco Induced PI3K/Akt Pathway in Head and Neck Cancer Cells. PLoS ONE, 2011, 6, e14728.	2.5	26
33	Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer. Cancer Treatment Reviews, 2015, 41, 277-288.	7.7	24
34	Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. EBioMedicine, 2019, 42, 375-385.	6.1	24
35	Clinical significance of TC21 overexpression in oral cancer. Journal of Oral Pathology and Medicine, 2010, 39, 477-485.	2.7	23
36	Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Management and Research, 2013, 5, 197.	1.9	22

#	Article	IF	Citations
37	Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity. Journal of the National Cancer Institute, 2019, 111, 233-244.	6.3	21
38	MUC4 is negatively regulated through the Wnt/Î²-catenin pathway via the Notch effector Hath1 in colorectal cancer. Genes and Cancer, 2016, 7, 154-168.	1.9	18
39	Exploring Dysregulated Signaling Pathways in Cancer. Current Pharmaceutical Design, 2020, 26, 429-445.	1.9	18
40	Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring. Cancer Letters, 2021, 510, 79-92.	7.2	16
41	Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma. International Journal of Clinical Oncology, 2015, 20, 298-307.	2.2	15
42	Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer. Journal of Translational Medicine, 2020, 18, 471.	4.4	15
43	Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188362.	7.4	13
44	Novel therapies hijack the bloodâ€"brain barrier to eradicate glioblastoma cancer stem cells. Carcinogenesis, 2019, 40, 2-14.	2.8	12
45	miRNAs as novel immunoregulators in cancer. Seminars in Cell and Developmental Biology, 2022, 124, 3-14.	5.0	11
46	Differential mutation spectrum and immune landscape in African Americans versus Whites: A possible determinant to health disparity in head and neck cancer. Cancer Letters, 2020, 492, 44-53.	7.2	10
47	Silicon: A Multitalented Micronutrient in OMICS Perspective â€" An Update. Current Proteomics, 2012, 9, 245-254.	0.3	9
48	Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 335.	8.6	8
49	Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 356.	8.6	8
50	Recent Advances in Head and Neck Tumor Microenvironmentâ€"Based Therapy. Advances in Experimental Medicine and Biology, 2020, 1296, 11-31.	1.6	3
51	Receptor Tyrosine Kinase Signaling Pathways as a Goldmine for Targeted Therapy in Head and Neck Cancers. , 2021, , 163-184.		1
52	Abstract 4044: MUC4 knockdown induces cellular senescence in head and neck cancer cells.. , 2013, , .		0
53	Abstract 1726: Targeting pancreatic cancer stem cells by afatinib in organoid culture. , 2016, , .		0
54	Abstract 719: Pathobiological implications of Trefoil Factors in the progression and metastasis of pancreatic cancer. , 2017, , .		0

#	Article	IF	Citations
55	Abstract 1909: NR4A2 role in head and neck cancer: Mechanistic and functional analysis. , 2018, , .		0
56	Abstract 4684: Afatinib targets glioblastoma stem cells by inhibiting EGFRVIII-cMet co-activation. , 2019, , .		0
57	Abstract A31: Deregulation of NOTCH 1/NR4A2 signaling axis in head and neck cancer pathogenesis. , 2020, , .		0
58	Recent Advances in Oral Cancer Research. , 2021, , 27-39.		0
59	Reply. Cancer Letters, 2022, 527, 193-194.	7.2	0